Each Sunday we feature a highlight reel of various articles posted on our website that week.

However, one significant problem has proven surprisingly durable: misdiagnosis of Type 1 diabetes (T1D). Estimates suggest ...

Now there is evidence that Hympavzi is also effective for people with hemophilia A and B who have developed inhibitors, a ...

A new influenza strain could fuel a severe flu season while a surge in measles cases threatens U.S. elimination status, ...

A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between ...

Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...

This effort to accelerate development can be clearly seen in how the agency is approaching biosimilars. In October 2025, the FDA issued a guidance update indicating that “switching” studies — a trial ...

High levels of IB6 are often found in NSCLC, making it a good target for treatment. A preclinical study found that in lung cancer, IB6 was correlated with interleukin-8 levels and promoted cancer cell ...

Independent practices face challenges from consolidation and policy shifts, with hybrid models offering autonomy while sharing financial risk. Value-based care in oncology prioritizes science, ...

Researchers at the National Institutes of Health (NIH) have developed a novel artificial intelligence and imaging method for retinal scans that reduces the amount of data needed by three-fourths, ...

Celecoxib improves disease-free and overall survival in ctDNA-positive stage III colon cancer patients when combined with ...

The findings challenge the conventional view that daytime sleepiness is always a result of insufficient sleep, poor sleep hygiene or classic sleep disorders. Instead, they suggest that internal ...